ATE218537T1 - Verbindungen mit wachstumshormon freisetzenden eigenschaften - Google Patents

Verbindungen mit wachstumshormon freisetzenden eigenschaften

Info

Publication number
ATE218537T1
ATE218537T1 AT97930368T AT97930368T ATE218537T1 AT E218537 T1 ATE218537 T1 AT E218537T1 AT 97930368 T AT97930368 T AT 97930368T AT 97930368 T AT97930368 T AT 97930368T AT E218537 T1 ATE218537 T1 AT E218537T1
Authority
AT
Austria
Prior art keywords
compounds
growth hormone
hormone releasing
releasing properties
formula
Prior art date
Application number
AT97930368T
Other languages
English (en)
Inventor
Bernd Peschke
Michael Ankersen
Thomas Kruse Hansen
Henning Thoegersen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Application granted granted Critical
Publication of ATE218537T1 publication Critical patent/ATE218537T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/06—Compounds containing any of the groups, e.g. semicarbazides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
AT97930368T 1996-07-22 1997-07-17 Verbindungen mit wachstumshormon freisetzenden eigenschaften ATE218537T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK80396 1996-07-22
PCT/DK1997/000314 WO1998003473A1 (en) 1996-07-22 1997-07-17 Compounds with growth hormone releasing properties

Publications (1)

Publication Number Publication Date
ATE218537T1 true ATE218537T1 (de) 2002-06-15

Family

ID=8097747

Family Applications (2)

Application Number Title Priority Date Filing Date
AT01123155T ATE304528T1 (de) 1996-07-22 1997-07-17 Verbindungen mit wachstumshormon-freisetzenden eigenschaften
AT97930368T ATE218537T1 (de) 1996-07-22 1997-07-17 Verbindungen mit wachstumshormon freisetzenden eigenschaften

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT01123155T ATE304528T1 (de) 1996-07-22 1997-07-17 Verbindungen mit wachstumshormon-freisetzenden eigenschaften

Country Status (8)

Country Link
US (3) US5922770A (de)
EP (2) EP1184370B1 (de)
JP (1) JP4425992B2 (de)
AT (2) ATE304528T1 (de)
AU (1) AU3434697A (de)
DE (2) DE69713109T2 (de)
WO (1) WO1998003473A1 (de)
ZA (1) ZA976371B (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1005484A1 (de) * 1997-06-20 2000-06-07 Novo Nordisk A/S Verbindungen mit wachstumshormon freisetzenden eigenschaften
US6127341A (en) * 1997-06-20 2000-10-03 Novo Nordisk A/S Compounds with growth hormone releasing properties
AU757217B2 (en) * 1998-05-11 2003-02-06 Helsinn Healthcare Sa Compounds with growth hormone releasing properties
TW450954B (en) * 1998-05-14 2001-08-21 Pharmacia & Amp Upjohn Company Phenylsulfonamide-phenylethylamines useful as dopamine receptors
WO2000001726A1 (en) * 1998-06-30 2000-01-13 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6919315B1 (en) 1998-06-30 2005-07-19 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6358951B1 (en) 1998-08-21 2002-03-19 Pfizer Inc. Growth hormone secretagogues
KR100699404B1 (ko) 1999-02-18 2007-03-23 가켄 세야쿠 가부시키가이샤 성장 호르몬 분비촉진제로서의 신규 아미드 유도체
UA73530C2 (uk) * 1999-11-10 2005-08-15 Ново Нордіск А/С Сполука з властивостями вивільнювати гормон росту
AU2001252958A1 (en) 2000-03-23 2001-10-03 Elan Pharmaceuticals, Inc. Compounds and methods to treat alzheimer's disease
US6992081B2 (en) 2000-03-23 2006-01-31 Elan Pharmaceuticals, Inc. Compounds to treat Alzheimer's disease
US6613801B2 (en) * 2000-05-30 2003-09-02 Transtech Pharma, Inc. Method for the synthesis of compounds of formula I and their uses thereof
EP1159964B1 (de) 2000-05-31 2009-10-28 Pfizer Products Inc. Verwendung von Wachstumshormonsekretagoga zur Förderung der Beweglichkeit des Verdauungstrakts
WO2002002506A2 (en) * 2000-06-30 2002-01-10 Elan Pharmaceuticals, Inc. Compounds to treat alzheimer's disease
PE20020276A1 (es) 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
US6846813B2 (en) * 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
US20030096864A1 (en) * 2000-06-30 2003-05-22 Fang Lawrence Y. Compounds to treat alzheimer's disease
EP1666452A2 (de) 2000-06-30 2006-06-07 Elan Pharmaceuticals, Inc. Verbindungen zur Behandlung der Alzheimerischen Krankheit
SK287304B6 (sk) * 2001-02-16 2010-06-07 Nps Pharmaceuticals, Inc. Substituované amínové deriváty ako inhibítory GlyT-1, farmaceutické prostriedky s ich obsahom, ich použitie, spôsob ich prípravy, ich medziprodukty a spôsob ich prípravy
CN1494425B (zh) * 2001-03-05 2011-12-07 特兰斯泰克制药公司 用作治疗剂的羧酰胺衍生物
WO2002069965A1 (en) * 2001-03-05 2002-09-12 Transtech Pharma, Inc. Benzimidazole derivatives as therapeutic agents
MXPA04000140A (es) * 2001-06-27 2004-06-03 Elan Pharm Inc Derivados de beta-hidroxiamina utiles en el tratamiento de enfermedad de alzheimer.
US20070213407A1 (en) * 2001-06-29 2007-09-13 Elan Pharmaceuticals And Pharmacia & Upjohn Company Llc Compounds to treat Alzheimer's disease
BR0306811A (pt) * 2002-01-11 2004-10-26 Sankyo Co Composto, éster farmacologicamente aceitável do mesmo, composição farmacêutica e métodos para prevenção ou tratamento de doenças autoimunes, da artrite reumatóide e da rejeição causada pelo transplante de vários órgãos em um mamìfero
US7230133B2 (en) 2003-05-01 2007-06-12 Bristol-Myers Squibb Company Malonamides and malonamide derivatives as modulators of chemokine receptor activity
WO2005000295A1 (en) * 2003-05-20 2005-01-06 Transtech Pharma, Inc. Rage antagonists as agents to reverse amyloidosis and diseases associated therewith
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
WO2005027913A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a growth hormone secretagogue
NZ549162A (en) 2004-02-24 2009-12-24 Sankyo Co Amino-pyrrol alcohol compounds
KR20070010151A (ko) * 2004-03-30 2007-01-22 사파이어 세라퓨틱스, 인크. 성장 호르몬 분비촉진제를 이용하여 ｃ-반응성 단백질을감소시키는 방법
EP1768976B1 (de) * 2004-06-29 2017-04-26 Helsinn Healthcare S.A. Kristalline formen von (3r)-1-(2-methylalanyl-d-tryptophyl)-3-(phenylmethyl)-3-piperidincarbonsäure-1,2,2-trimethylhydrazid
KR20130048793A (ko) * 2004-08-12 2013-05-10 헬신 세라퓨틱스 (유.에스.) 인크. 성장 호르몬 분비촉진제를 이용하여 위장관계의 운동성을 촉진하는 방법
CN101248184B (zh) 2005-08-25 2013-01-16 宇部兴产株式会社 光学活性（S或R）-α-氨基酸及光学活性（S或R）-α-氨基酸酯的制造方法
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
PT2118123E (pt) 2007-01-31 2016-02-10 Harvard College Péptidos de p53 estabilizados e suas utilizações
BRPI0807046A2 (pt) 2007-02-09 2015-05-26 Tranzyme Pharma Inc Composto, composição farmacêutica, métodos de tratar um distúrbio, uma doença cardiovascular e um paciente que sofre de motilidade gastrointestinal reduzida ou disfuncional e, kit.
JP2010518158A (ja) * 2007-02-13 2010-05-27 ヘルシン セラピューティクス（ユー．エス．），インコーポレイティド 成長ホルモン分泌促進物質を用いた細胞増殖性障害の治療方法
KR101623985B1 (ko) 2007-03-28 2016-05-25 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 스티칭된 폴리펩티드
TWI429436B (zh) * 2007-04-10 2014-03-11 Helsinn Therapeutics Us Inc 使用生長激素促泌素治療或預防嘔吐之方法
UA105657C2 (uk) 2009-02-27 2014-06-10 Хелсінн Терапьютікс (Ю.Ес.), Інк. Поліпшені способи лікування мігрені на основі анамореліну
US8580833B2 (en) 2009-09-30 2013-11-12 Transtech Pharma, Inc. Substituted imidazole derivatives and methods of use thereof
PT2603600T (pt) 2010-08-13 2019-02-27 Aileron Therapeutics Inc Macrociclos peptidomiméticos
CN104039342A (zh) 2011-10-18 2014-09-10 爱勒让治疗公司 拟肽大环化合物
EP2822572B1 (de) 2012-02-15 2020-06-10 Aileron Therapeutics, Inc. Peptidomimetische makrozyklen
EP2819688A4 (de) 2012-02-15 2015-10-28 Aileron Therapeutics Inc Triazol- und thioethervernetzte peptidomimetische makrozyklen
US9717710B2 (en) 2012-10-05 2017-08-01 Vtv Therapeutics Llc Treatment of mild and moderate Alzheimer's disease
BR112015009470A2 (pt) 2012-11-01 2019-12-17 Aileron Therapeutics Inc aminoácidos dissubstituídos e seus métodos de preparação e uso
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
EP3197478A4 (de) 2014-09-24 2018-05-30 Aileron Therapeutics, Inc. Peptidomimetische makrozyklen und verwendungen davon
US10253067B2 (en) 2015-03-20 2019-04-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US20170121385A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
EP3414783B1 (de) 2016-02-09 2021-08-18 Lumeova, Inc Vorrichtungen und systeme zur ultrabreitbandigen, drahtlosen optischen hochgeschwindigkeitsübertragung
WO2019190822A1 (en) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
WO2019190823A1 (en) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chlorophenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
WO2020076668A1 (en) 2018-10-10 2020-04-16 Vtv Therapeutics Llc Metabolites of [3-(4-{2-butyl-l-[4-(4-chloro-phenoxy)-phenyl]-lh-imidazol-4-yl } -phen ox y)-prop yl] -diethyl-amine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2179597A1 (en) * 1993-12-23 1995-06-29 Nils Langeland Johansen Compounds with growth hormone releasing properties
PL186511B1 (pl) * 1995-01-27 2004-01-30 Novo Nordisk As Nowe związki peptydowe, kompozycje farmaceutycznedo pobudzania uwalniania hormonu wzrostu i zastosowanie tych związków do wytwarzania leku do pobudzania uwalniania hormonu wzrostu
WO1997023508A1 (en) * 1995-12-22 1997-07-03 Novo Nordisk A/S Compounds with growth hormone releasing properties

Also Published As

Publication number Publication date
DE69713109D1 (de) 2002-07-11
EP0923539B1 (de) 2002-06-05
EP0923539A1 (de) 1999-06-23
EP1184370A3 (de) 2002-03-27
ATE304528T1 (de) 2005-09-15
DE69713109T2 (de) 2003-01-02
AU3434697A (en) 1998-02-10
US6127354A (en) 2000-10-03
DE69734215D1 (de) 2005-10-20
ZA976371B (en) 1998-01-22
DE69734215T2 (de) 2006-06-29
US6274584B1 (en) 2001-08-14
EP1184370A2 (de) 2002-03-06
JP4425992B2 (ja) 2010-03-03
WO1998003473A1 (en) 1998-01-29
US5922770A (en) 1999-07-13
JP2000515517A (ja) 2000-11-21
EP1184370B1 (de) 2005-09-14

Similar Documents

Publication Publication Date Title
ATE304528T1 (de) Verbindungen mit wachstumshormon-freisetzenden eigenschaften
MY113488A (en) Compounds with growth hormone releasing properties
RU94016393A (ru) Пептиды, обладающие способностью к стимулированию высвобождения гормона роста, способ получения, фармацевтическая композиция, способ лечения
DE69825292D1 (de) Verwendung von inosine zur herstellung eines medikamentes zur stimulierung des axonwachstums von zns-neuronen
EP0740650A4 (de) Kombinierte wirkstoffe als methode zur gezielten wirkstoff-freisetzung
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
BG106095A (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
DE69333607D1 (de) Vorrichtung zur Herstellung von vorgefüllten, sterilen Abgabevorrichtungen
FI20050467A (fi) Menetelmiä kasvuhormonin vapautumisen edistämieksi eläimessä
DE3382458D1 (de) Haarwuchsmittel.
SE9401406L (sv) Farmaceutiska produkter för att bota tumörsjukdomar samt förfarande för framställning av desamma
NO991736L (no) Bioaktive peptider, anvendelse derav samt fremstilling av slike
IT8619055A0 (it) Composizioni farmaceutiche comprendenti peptidi del gruppo colecistochinina-cerulina per il trattamento terapeutico degli statidi shock e dell'insufficienza respiratoria e cardiocircolatoria.
DE69716223D1 (de) Vorrichtung zur Herstellung von medizinischen Pflastern zur perkutanen Verabreichung
DE69007065D1 (de) Verwendung von Diadenosin-5',5'''-p1,p4-tetraphosphat zur Herstellung eines Arzneimittels zur Behandlung von Herzkrankheiten.
ATE316379T1 (de) Oxyhuminsäure und ihre verwendung zur behandlung von verschiedenenen störungen
GR3032224T3 (en) Therapeutic agent for threatened abortion.
YU60199A (sh) Nove soli bpc peptida sa organo-zaštitnom aktivnošću, postupak za njihovo dobijanje i njihova primena u terapiji
DE69921611D1 (de) Verbindungen mit wachstumshormon-freisetzenden eigenschaften
CO4930262A1 (es) Producto farmaceutico cristalino, su preparacion y uso como sustancia terapeutica
FI102810B1 (fi) Aine eläimen ihon käsittelyyn
Ristau et al. Bovine leucosis virus challenge infection of calves following application of BL-3 cells
BG103997A (en) Drug delivery device and methods for the treatment of viral and microbial infections and wasting syndromes
RU2001113054A (ru) Способ лечения послеродового острого гнойно-катарального эндометрита коров
MX9800686A (es) Nueva proteina hmw humana mp52s.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties